Analyst firms · Wolfe Research · CLDX
Wolfe Research CLDX price target and rating history
Celldex Therapeutics Inc. (CLDX) · Health Care
Wolfe Research rates Celldex Therapeutics Inc. (CLDX) Outperform with a $44 price target, as of its latest action on Mar 23, 2026. It has published 3 rating actions on CLDX since June 2024, including 1 upgrade and 1 downgrade. Across 3 firms with a CLDX price target in the last 12 months, the median target is $45. Wolfe Research's $44 is 2% below that.
- Current rating
- Outperform
- Price target
- $44
- Median target, all firms
- $45
- Actions on CLDX
- 3
Wolfe Research price target on CLDX
Every Wolfe Research rating on CLDX
- Mar 23, 2026
- Sep 27, 2024
- Jun 11, 2024
How other firms rate CLDX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $64 | Sep 22, 2026 |
| Barclays | Overweight | $45 | Apr 20, 2026 |
| Wolfe Research | Outperform | $44 | Mar 23, 2026 |
Questions about Wolfe Research and CLDX
- What is Wolfe Research's price target for CLDX?
- Wolfe Research's latest stated price target for Celldex Therapeutics Inc. (CLDX) is $44, from its action on Mar 23, 2026.
- What is Wolfe Research's rating on CLDX?
- Wolfe Research rates CLDX Outperform, a bullish rating, as of Mar 23, 2026.
- When did Wolfe Research last change its view on CLDX?
- On Mar 23, 2026, Wolfe Research upgrades to Outperform from Peer Perform, price target $44.
- How does Wolfe Research's CLDX target compare with other analysts?
- Across 3 firms with a CLDX price target in the last 12 months, the median target is $45. Wolfe Research's $44 is 2% below that.
More CLDX rating histories
All Wolfe Research ratingsCLDX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.